



CORRECTION

Correction to: Effect of Golimumab Dose Escalation in Japanese Patients With Rheumatoid Arthritis: Post-Hoc Analysis of Post-Marketing Surveillance Data

Hirohito Shimizu · Hisanori Kobayashi · Masayoshi Kanbori · Yutaka Ishii

Published online: October 8, 2020
© The Author(s) 2020

Correction to: Rheumatol Ther (2020) 7:311–325
<https://doi.org/10.1007/s40744-020-00198-4>

Under Results section, heading: Effectiveness of GLM Stratified by the Time to Dose Escalation, the remission based on values of DAS28, SDAI, and CDAI was published incorrectly. The correct values are: 16.1%, 5.0% and 4.3%.

And also, the title of the Table 2 is incorrect. The correct title is Univariate and multivariate logistic regression analyses of patient variables associated with likelihood of achieving a good or moderate EULAR response after 24 weeks of GLM treatment.

OPEN ACCESS

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

The original article can be found online at <https://doi.org/10.1007/s40744-020-00198-4>.

H. Shimizu (✉) · Y. Ishii
Medical Affairs Division, Immunology Department,
Janssen Pharmaceutical K.K, Tokyo, Japan
e-mail: hshimi10@its.jnj.com

H. Kobayashi
Clinical Science Division, External Collaboration
and Portfolio Management Department, R&D
Janssen Pharmaceutical K.K., Tokyo, Japan

M. Kanbori
Japan Safety & Surveillance Division, Research &
Development Division, Janssen Pharmaceutical
K.K., Tokyo, Japan